158 related articles for article (PubMed ID: 7908021)
1. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.
Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W
J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
3. Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans.
Brandt-Rauf PW; Luo JC; Carney WP; Smith S; De Vivo I; Milling C; Hemminki K; Koskinen H; Vainio H; Neugut AI
Int J Cancer; 1994 Feb; 56(3):383-6. PubMed ID: 7906254
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
Meden H; Kuhn W
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
[TBL] [Abstract][Full Text] [Related]
6. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients.
Kynast B; Binder L; Marx D; Zoll B; Schmoll HJ; Oellerich M; Schauer A
J Cancer Res Clin Oncol; 1993; 119(5):249-52. PubMed ID: 8095050
[TBL] [Abstract][Full Text] [Related]
7. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
8. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.
Meden H; Marx D; Raab T; Kron M; Schauer A; Kuhn W
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):167-78. PubMed ID: 8556578
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies.
Meden H; Mielke S; Schauer A; Kuhn W
In Vivo; 1997; 11(1):51-4. PubMed ID: 9067773
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of p185 is not related to erbB2 amplification in ovarian cancer.
Morali F; Cattabeni M; Tagliabue E; Campiglio M; Menard S; Marzola M; Lucchini V; Colombo N; Mangioni C; Redaelli L
Ann Oncol; 1993 Nov; 4(9):775-9. PubMed ID: 7904177
[TBL] [Abstract][Full Text] [Related]
11. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
Leitzel K; Teramoto Y; Sampson E; Mauceri J; Langton BC; Demers L; Podczaski E; Harvey H; Shambaugh S; Volas G
J Clin Oncol; 1992 Sep; 10(9):1436-43. PubMed ID: 1355522
[TBL] [Abstract][Full Text] [Related]
12. Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis.
Mielke S; Meden H; Kuhn W
Med Hypotheses; 1998 May; 50(5):359-62. PubMed ID: 9681912
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression.
Meden H; Marx D; Rath W; Kron M; Fattahi-Meibodi A; Hinney B; Kuhn W; Schauer A
Int J Gynecol Pathol; 1994 Jan; 13(1):45-53. PubMed ID: 7906681
[TBL] [Abstract][Full Text] [Related]
14. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
15. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
16. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients].
Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438
[TBL] [Abstract][Full Text] [Related]
17. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
18. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of estrogens on c-erbB-2 oncoprotein levels in chorionic villous tissue and maternal serum.
Mielke S; Meden H; Marx D; Wuttke W; Kuhn W
Gynecol Endocrinol; 1997 Aug; 11(4):237-41. PubMed ID: 9272419
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the c-neu proto-oncogene related protein, p185, in the serum of primary epithelial ovarian cancer patients.
Fisken J; Roulston JE; Beattie G; Hayes DF; Leonard RC
Int J Gynecol Cancer; 1992 May; 2(3):134-140. PubMed ID: 11576248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
